BTC $78,837.09 -0.25%
ETH $2,493.69 +1.05%
BNB $702.41 +0.90%
XRP $1.41 -2.76%
SOL $101.24 +4.21%
TRX $0.3343 -0.98%
DOGE $0.0869 +0.15%
ADA $0.2095 -0.94%
BCH $266.62 -0.08%
LINK $11.55 +0.83%
HYPE $80.97 -1.15%
AAVE $124.92 -2.14%
SUI $0.7509 -1.37%
XLM $0.1829 -0.84%
ZEC $779.09 -0.90%
BTC $78,837.09 -0.25%
ETH $2,493.69 +1.05%
BNB $702.41 +0.90%
XRP $1.41 -2.76%
SOL $101.24 +4.21%
TRX $0.3343 -0.98%
DOGE $0.0869 +0.15%
ADA $0.2095 -0.94%
BCH $266.62 -0.08%
LINK $11.55 +0.83%
HYPE $80.97 -1.15%
AAVE $124.92 -2.14%
SUI $0.7509 -1.37%
XLM $0.1829 -0.84%
ZEC $779.09 -0.90%

Sonnet Biotherapeutics 获股东批准与 Hyperliquid Strategies Inc 进行业务合并

2025-12-02 22:26:45

ChainCatcher 消息,据市场消息,纳斯达克上市生物科技公司 Sonnet Biotherapeutics 已获得股东批准,拟与 Hyperliquid Strategies Inc 进行业务合并。

此前消息,Hyperliquid Strategies 提交 S-1 文件,拟募资最高 10 亿美元或用于购入 HYPE 代币。

app_icon
ChainCatcher Building the Web3 world with innovations.